News Celgene hopes device + drug can tackle aggressive brain tumo... Novocure's Optune will be tested alongside investigational Celgene drug marizomib.
News Head patch device Optune improves brain cancer survival Median overall survival improved from 15 months to 21 months when combined with chemotherapy.
News Electrical patch device shows promise against ovarian cancer Novocure's Optune device shown to be safe and tolerable in recurrent ovarian cancer.
News FDA chooses flu vaccine strains despite cancelled meeting The FDA has released its recommendations on the composition of influenza vaccines for the 2025-26 season – without the input of its external advisors.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
